Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems

• Published in: Vaccines (Basel) Vol. 10; no. 1; p. 96
• Main Authors: Merkuleva, Iuliia A., Shcherbakov, Dmitry N., Borgoyakova, Mariya B., Shanshin, Daniil V., Rudometov, Andrey P., Karpenko, Larisa I., Belenkaya, Svetlana V., Isaeva, Anastasiya A., Nesmeyanova, Valentina S., Kazachinskaia, Elena I., Volosnikova, Ekaterina A., Esina, Tatiana I., Zaykovskaya, Anna V., Pyankov, Oleg V., Borisevich, Sophia S., Shelemba, Arseniya A., Chikaev, Anton N., Ilyichev, Alexander A.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.01.2022; MDPI
• Subjects: Antibodies; Antigens; Binding; Bioethics; Chromatography; Cloning; Coronaviruses; COVID-19; COVID-19 vaccines; E coli; Enzyme-linked immunosorbent assay; Gene expression; Immune response; Immune response (humoral); Immune system; Immunization; Immunogenicity; Mammals; Neutralization; Pandemics; Plasmids; Protein S; Proteins; receptor-binding domain; Receptors; S protein; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; subunit vaccines; Vaccines; Viral infections; United States > US; COVID-19; subunit vaccines; SARS-CoV-2; S protein; receptor-binding domain

The receptor-binding domain (RBD) of the protein S SARS-CoV-2 is considered to be one of the appealing targets for developing a vaccine against COVID-19. The choice of an expression system is essential when developing subunit vaccines, as it ensures the effective synthesis of the correctly folded ta...